Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9302281 | 1.00 | HSPD1 (0.42) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL7050626 | 0.87 | CPT2 (0.39) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL11824865 | 0.85 | HSPD1 (0.43) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL2979037 | 0.82 | CPT2 (0.53) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL17239649 | 0.80 | HSPD1 (0.44) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL260454 | 0.78 | CPT2 (0.41) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL10535147 | 0.78 | CPT2 (0.41) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL10535133 | 0.78 | CPT2 (0.41) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL28928385 | 0.78 | HSPD1 (0.49) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL9954809 | 0.78 | HSPD1 (0.49) | HSPD1BLMHSPE1MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558280-B1 | MIGRAINE PREVENTION AND TREATMENT | UNIV KINDERSPITAL BEIDER BASEL (CH) | 2023-06-07 | — | — | EP | claimed |
| EP-3296284-B1 | NON-THERAPEUTICAL USE OF HYDROXYBUTYRATE ESTER | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRES BY THE SECRETARY OF HEALTH AND HUMAN SERVIC (US) | 2021-12-01 | — | — | EP | claimed |
| EP-2419519-B1 | PROCESS FOR PRODUCING (3R)-HYDROXYBUTYL (3R)-HYDROXYBUTYRATE BY ENZYMATIC ENANTIOSELECTIVE REDUCTION EMPLOYING ALCOHOL DEHYDROGENASES OR KETO REDUCTASES | UNIV OXFORD INNOVATION LTD (GB) | 2019-03-27 | — | — | EP | claimed |
| EP-2328858-B1 | DRINK COMPRISING HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF | UNIV OXFORD INNOVATION LTD (GB) | 2017-10-11 | — | — | EP | claimed |
| US-20120064611-A1 | Process For The Preparation of (3R)-Hydroxybutyl (3R) -Hydroxybutyrate By Enzymatic Enantioselective Reduction Employing Lactobacillus Brevis Alcohol Dehydrogenase | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2012-03-15 | — | — | US | claimed |
| EP-2419519-A1 | PROCESS FOR THE PREPARATION OF (3R)-HYDR0XYBUTYL (3R) -HYDROXYBUTYRATE BY ENZYMATIC ENANTIOSELECTIVE REDUCTION EMPLOYING LACTOBACILLUS BREVIS ALCOHOL DEHYDROGENASE | Isis Innovation Limited (GB) | 2012-02-22 | — | — | EP | claimed |
| US-20110237666-A1 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2011-09-29 | — | — | US | claimed |
| US-12577591-B2 | Microorganisms and methods for increasing co-factors | GENOMATICA, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4662192-A1 | MICROORGANISMS AND METHODS FOR REDUCING BY-PRODUCTS | Genomatica, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168072-A1 | MICROORGANISMS AND METHODS FOR REDUCING BY-PRODUCTS | GENOMATICA, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240150798-A1 | MICROORGANISMS AND METHODS FOR PRODUCING (3R)-HYDROXYBUTYL (3R)-HYDROXYBUTYRATE | GENOMATICA INC (US) | 2024-05-09 | — | — | US | disclosed |
| US-11814664-B2 | Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate | GENOMATICA, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230287435-A1 | MICROORGANISMS AND METHODS FOR REDUCING BY-PRODUCTS | AGAIN BIO APS (DK) | 2023-09-14 | — | — | US | disclosed |
| US-9034613-B2 | Process for the preparation of (3R)-hydroxybutyl (3R)-hydroxybutyrate by enzymatic enantioselective reduction employing Lactobacillus brevis alcohol dehydrogenase | ISIS INNOVATION LIMITED | 2015-05-19 | — | — | US | disclosed |
| US-20120064611-A1 | Process For The Preparation of (3R)-Hydroxybutyl (3R) -Hydroxybutyrate By Enzymatic Enantioselective Reduction Employing Lactobacillus Brevis Alcohol Dehydrogenase | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-20120064611-A1 | Process For The Preparation of (3R)-Hydroxybutyl (3R) -Hydroxybutyrate By Enzymatic Enantioselective Reduction Employing Lactobacillus Brevis Alcohol Dehydrogenase | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2419519-A1 | PROCESS FOR THE PREPARATION OF (3R)-HYDR0XYBUTYL (3R) -HYDROXYBUTYRATE BY ENZYMATIC ENANTIOSELECTIVE REDUCTION EMPLOYING LACTOBACILLUS BREVIS ALCOHOL DEHYDROGENASE | Isis Innovation Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| EP-2419519-A1 | PROCESS FOR THE PREPARATION OF (3R)-HYDR0XYBUTYL (3R) -HYDROXYBUTYRATE BY ENZYMATIC ENANTIOSELECTIVE REDUCTION EMPLOYING LACTOBACILLUS BREVIS ALCOHOL DEHYDROGENASE | Isis Innovation Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20110237666-A1 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110237666-A1 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064611-A1 | Process For The Preparation of (3R)-Hydroxybutyl (3R) -Hydroxybutyrate By Enzymatic Enantioselective Reduction Employing Lactobacillus Brevis Alcohol Dehydrogenase | ADH5, ADH1A, ADH1C | HSPD1 626/4885BLM 1399/4885HSPE1 1137/4885 |
| US-20240150798-A1 | MICROORGANISMS AND METHODS FOR PRODUCING (3R)-HYDROXYBUTYL (3R)-HYDROXYBUTYRATE | ACACB, GRHPR, HSD17B10 | HSPD1 1183/4885BLM 3948/4885HSPE1 1608/4885 |
| US-20110237666-A1 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF | FFAR3, FFAR1, PYGB | HSPD1 227/4885BLM 4736/4885HSPE1 369/4885 |
| US-11814664-B2 | Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate | ACACB, GRHPR, HSD17B10 | HSPD1 1183/4885BLM 3948/4885HSPE1 1608/4885 |
| US-12577591-B2 | Microorganisms and methods for increasing co-factors | ABAT, HADHB, MMAB | HSPD1 566/4885BLM 4269/4885HSPE1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.